Tadalafil 171596-29-5 Kurapa Erectile Dysfunction muVarume
Product Detail
| Zita | Tadalafil |
| CAS nhamba | 171596-29-5 |
| Molecular formula | C22H19N3O4 |
| Molecular uremu | 389.4 |
| Nhamba yeEINECS | 687-782-2 |
| Kutenderera chaiko | D20+71.0° |
| Density | 1.51±0.1g/cm3(Zvakafanotaurwa) |
| Kuchengetedza mamiriro | 2-8°C |
| Form | Upfu |
| Acidity coefficient | (pKa) 16.68±0.40 (Zvakafanotaurwa) |
| Kunyungudika kwemvura | DMSO: soluble 20mg/mL, |
Mashoko anoreva zvakafanana
TADALAFIL; CIALIS; IC 351;(6R,12AR)-6-(benzo[d][1,3]dioxol-5-yl)-2-methyl-2,3,12,12a-tetrahydropyrazino[1',2':1,6]pyrido;GF 196960;ICOS 351;Tildenafil;
Pharmacological Effect
Tadalafil (Tadalafil, Tadalafil) ine molecular formula yeC22H19N3O4 uye molecular uremu hwe389.4. Yakave ichishandiswa zvakanyanya mukurapa kwemurume erectile dysfunction kubvira 2003, ine zita rekutengesa reCialis (Cialis). Muna Chikumi 2009, iyo FDA yakabvumidza tadalafil muUnited States kurapwa kwevarwere vane pulmonary arterial hypertension (PAH) pasi pezita rekutengesa Adcirca. Tadalafil yakaunzwa mu2003 semushonga wekurapa ED. Zvinotora maminitsi makumi matatu mushure mekutonga, asi mhedzisiro yayo yakanaka ndeye 2h mushure mekutanga kwechiito, uye mhedzisiro inogona kugara kwe36h, uye mhedzisiro yayo haina kukanganiswa nekudya. Muyero we tadalafil ndeye 10 kana 20 mg, iyo inokurudzirwa yekutanga dose ndeye 10 mg, uye iyo dose inogadziriswa maererano nemhinduro yemurwere uye maitiro asina kunaka. Zvidzidzo zvepamberi-musika zvakaratidza kuti mushure mekutonga kwemuromo kwe10 kana 20 mg ye tadalafil kwemavhiki e12, mitengo inoshanda ndeye 67% uye 81%, zvichiteerana. Zvidzidzo zvakawanda zvakaratidza kuti tadalafil ine zvirinani kushanda mukurapa kweED.
Erectile Dysfunction: Tadalafil inosarudza phosphodiesterase type 5 (PDE5) yakafanana ne sildenafil, asi chimiro chayo chakasiyana nechekupedzisira, uye kudya kwemafuta akawanda hakuvhiringidzi kubatwa kwayo. Pasi pechiito chekukurudzira zvepabonde, nitric oxide synthase (NOS) mupenile nerve endings uye vascular endothelial masero anokonzera kuumbwa kwe nitric oxide (NO) kubva kune substrate L-arginine. NO activate guanylate cyclase, iyo inoshandura guanosine triphosphate kuita cyclic guanosine monophosphate (cGMP), nokudaro activate cyclic guanosine monophosphate-inotsamira protein kinase, zvichikonzera kudzikira kwehuwandu hwecalcium ions mumasero akatsetseka emhasuru, zvichikonzera kuti corpus cavernosum Erection inoitika nekuda kwekuzorora kwemhasuru yakatsetseka. Phosphodiesterase type 5 (PDE5) inodzikisira cGMP kuita zvigadzirwa zvisingaite, zvichiita kuti mboro ive isina simba. Tadalafil inhibits kuderedzwa kwePDE5, zvichiita kuti kuunganidza cGMP, iyo inozorodza musuru wakatsetseka we corpus cavernosum, zvichiita kuti penile erection. Sezvo ma nitrate ari NO vanopa, kushandiswa kwakasanganiswa netadalafil kuchawedzera zvakanyanya mwero wecGMP uye kutungamirira kune yakanyanya hypotension. Nokudaro, kushandiswa kwakabatanidzwa kwezviviri kunopesana mumakiriniki maitiro.
Tadalafil inoshanda nekudzivisa PDES. GMP yakaderedzwa, saka kushandiswa kwakasanganiswa nenitrate kunogona kukonzera kuderera kwakanyanya muBP uye kuwedzera njodzi yesyncope. CY3PA4 inducers ichaderedza bioavailability ye tadanafil, uye kusanganiswa ne rifampicin, cimetidine, erythromycin, clarithromycin, itracon, ketocon, uye HVI protease inhibitors inogona kuwedzera Kuwanda kweropa remushonga kunofanira kugadziriswa. Parizvino, hapana mishumo yekuti iyo pharmacokinetic parameters yechigadzirwa ichi inobatwa nekudya uye doro.
